Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-CMÜLLER, M. C; GATTERMANN, N; KRAUSE, S. W et al.Leukemia. 2003, Vol 17, Num 12, pp 2392-2400, issn 0887-6924, 9 p.Article

Pegylated liposomal doxorubicin in combination with mitomycin C, infusional 5-fluorouracil and sodium folinic acid. A phase-I-study in patients with upper gastrointestinal cancerHOFHEINZ, R-D; WILLER, A; WEISSER, A et al.British journal of cancer. 2004, Vol 90, Num 10, pp 1893-1897, issn 0007-0920, 5 p.Article

Imatinib sensitivity as a consequence of a CSF1R-Y571D mutation and CSF1/CSF1R signaling abnormalities in the cell line GDM1CHASE, A; SCHULTHEIS, B; KREIL, S et al.Leukemia. 2009, Vol 23, Num 2, pp 358-364, issn 0887-6924, 7 p.Article

Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon αMERX, K; MÜLLER, M. C; HEHLMANN, R et al.Leukemia. 2002, Vol 16, Num 9, pp 1579-1583, issn 0887-6924Article

Safety and efficacy of STI-571 (imatinib mesylate) in patients with bar/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT) : Spotlight on signal transduction inhibitors: Basic aspects and therapeutics implicationsFISCHER, T; REIFENRATH, C; HEHLMANN, R et al.Leukemia. 2002, Vol 16, Num 7, pp 1220-1228, issn 0887-6924Article

Analysis of genomic breakpoints in p190 and p210 BCR-ABL indicate distinct mechanisms of formationSCORE, J; CALASANZ, M. J; WIEMELS, J et al.Leukemia. 2010, Vol 24, Num 10, pp 1742-1750, issn 0887-6924, 9 p.Article

The severity of FlP1L1 -PDGFRA -positive chronic eosinophilic leukaemia is associated with polymorphic variation at the IL5RA locusBURGSTALLER, S; KREIL, S; WALZ, C et al.Leukemia. 2007, Vol 21, Num 12, pp 2428-2432, issn 0887-6924, 5 p.Article

Capecitabine in combination with mitomycin C in patients with gastrointestinal cancer: results of an extended multicentre phase-1 trialHOFHEINZ, R.-D; HARTMANN, J. T; HOCHHAUS, A et al.British journal of cancer. 2004, Vol 91, Num 5, pp 834-838, issn 0007-0920, 5 p.Article

Molecular monitoring of response to imatinib (Glivec®) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission : Spotlight on imatinib as a model for signal transduction inhibitorsPASCHKA, P; MÜLLER, M. C; GSCHAIDMEIER, H et al.Leukemia. 2003, Vol 17, Num 9, pp 1687-1694, issn 0887-6924, 8 p.Article

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapyHOCHHAUS, A; KREIL, S; GSCHAIDMEIER, H et al.Leukemia. 2002, Vol 16, Num 11, pp 2190-2196, issn 0887-6924Article

Improvement of molecular monitoring of residual disease in leukemias by bedside RNA stabilizationMÜLLER, M. C; MERX, K; WEISSER, A et al.Leukemia. 2002, Vol 16, Num 12, pp 2395-2399, issn 0887-6924, 5 p.Article